InvestSMART

Ryder Capital Limited (ASX:RYD)

ALERT: Price-sensitive ASX Announcement for RYD
Current share price for RYD : $2.300 0.22 (10.58%)+
Announcement
Release
14 Aug 2026 9:49AM
Price at Release
$2.080
Full Release
download
Summary
The FY2026 Annual Report for Memphasys Limited highlights a challenging financial year with revenue of $531,980, a significant decrease from the previous year's $1,273,842. The company reported a net loss of $4,941,913 for FY2025, up from $4,442,021 in FY2024. Total comprehensive loss for the year was $4,942,913, with accumulated losses amounting to $55,247,604 by the end of the financial year. Cash and cash equivalents stood at $298,302. The report notes a net tangible liability per security of (0.2) cents. The financial statements were still under audit at the time of reporting, with the Annual General Meeting set for November 20, 2025. The company's strategic focus is on commercializing the Felix™ System for male fertility, supported by strategic partnerships to aid international expansion.
Key Points
  • Revenue of $531,980 for FY2025, down from $1,273,842 in FY2024.
  • Net loss for FY2025 was $4,941,913, compared to $4,442,021 in FY2024.
  • Total comprehensive loss for FY2025 was $4,942,913.
  • Accumulated losses at end of FY2025 were $55,247,604.
  • Cash and cash equivalents at end of FY2025 were $298,302.
  • Net tangible liabilities per security were (0.2) cents.
  • The financial statements are in the process of being audited.
  • Annual General Meeting scheduled for November 20, 2025.
  • Focus on commercialising the Felix™ System for male fertility.
  • Strategic partnerships for international expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.